pubmed-article:1915801 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:1915801 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:1915801 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
pubmed-article:1915801 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
pubmed-article:1915801 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
pubmed-article:1915801 | lifeskim:mentions | umls-concept:C1136085 | lld:lifeskim |
pubmed-article:1915801 | lifeskim:mentions | umls-concept:C1145667 | lld:lifeskim |
pubmed-article:1915801 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
pubmed-article:1915801 | lifeskim:mentions | umls-concept:C0443737 | lld:lifeskim |
pubmed-article:1915801 | lifeskim:mentions | umls-concept:C1515021 | lld:lifeskim |
pubmed-article:1915801 | lifeskim:mentions | umls-concept:C1516240 | lld:lifeskim |
pubmed-article:1915801 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:1915801 | pubmed:dateCreated | 1991-11-1 | lld:pubmed |
pubmed-article:1915801 | pubmed:abstractText | The presence of T cells binding F(ab')2 fragments of the idiotypic immunoglobulin was examined by immunofluorescence in peripheral blood of patients with monoclonal gammopathy. In 3 out of 11 tested patients, 1-15% idiotype-binding T cells of either CD4 or CD8 phenotype were found. In 1 patient both a CD4+ and a CD8+ idiotype-binding T-cell fraction were present. In 1 patient the idiotype-binding T cells also reacted with a mAb directed against the variable parts of the TCR alpha or beta chains, further indicating a clonal origin at the alpha/beta level. 3 patients had an expanded predominant T-cell receptor V gene usage based on the reactivity with the limited panel of TCR mAb, but these "clonal" T cells did not bind the idiotype. The study supports the existence of idiotype-specific T cells in peripheral blood of patients with monoclonal gammopathy. Such cells might have a regulatory role on the monoclonal B-cell clone and may be an important target for immunotherapy. | lld:pubmed |
pubmed-article:1915801 | pubmed:language | eng | lld:pubmed |
pubmed-article:1915801 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1915801 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:1915801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1915801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1915801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1915801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1915801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1915801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1915801 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1915801 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:1915801 | pubmed:month | Sep | lld:pubmed |
pubmed-article:1915801 | pubmed:issn | 0902-4441 | lld:pubmed |
pubmed-article:1915801 | pubmed:author | pubmed-author:HolmGG | lld:pubmed |
pubmed-article:1915801 | pubmed:author | pubmed-author:WigzellHH | lld:pubmed |
pubmed-article:1915801 | pubmed:author | pubmed-author:MellstedtHH | lld:pubmed |
pubmed-article:1915801 | pubmed:author | pubmed-author:LefvertA KAK | lld:pubmed |
pubmed-article:1915801 | pubmed:author | pubmed-author:JansonC HCH | lld:pubmed |
pubmed-article:1915801 | pubmed:author | pubmed-author:OsterborgAA | lld:pubmed |
pubmed-article:1915801 | pubmed:author | pubmed-author:BergenbrantSS | lld:pubmed |
pubmed-article:1915801 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:1915801 | pubmed:volume | 47 | lld:pubmed |
pubmed-article:1915801 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:1915801 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:1915801 | pubmed:pagination | 185-91 | lld:pubmed |
pubmed-article:1915801 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:meshHeading | pubmed-meshheading:1915801-... | lld:pubmed |
pubmed-article:1915801 | pubmed:year | 1991 | lld:pubmed |
pubmed-article:1915801 | pubmed:articleTitle | Peripheral blood T lymphocytes in patients with monoclonal gammopathies: expanded subsets as depicted by capacity to bind to autologous monoclonal immunoglobulins or reactivity with anti-V gene-restricted antibodies. | lld:pubmed |
pubmed-article:1915801 | pubmed:affiliation | Department of Oncology (Radiumhemmet), Karolinska Institute, Stockholm, Sweden. | lld:pubmed |
pubmed-article:1915801 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:1915801 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1915801 | lld:pubmed |